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Background: One of the most discomfortable dose-limiting adverse reactions of effective drugs for the
treatment of solid tumors is a peripheral neuropathy which is the main reason for dose reduction and
discontinuation of the therapy. We identified oxidative stress as one target of oxaliplatin toxicity in the
search of possible adjuvant therapies to prevent neuropathy and alleviate pain. Therefore, we studied an
effective SOD mimetic compound, MnL4, as a possible adjuvant treatment in in vitro cellular cultures and
in vivo on a rat model of oxaliplatin-induced neuropathy.
Methods and results: All rat manipulations were carried out according to the European Community
guidelines for animal care. We performed experiments on SH-SY5Y, HT-29 and primary cortical rat as-
trocytes. Incubation with 100 mM oxaliplatin increased superoxide anion production and caspase 3/7
activity in the neuronal cell line SH-SY5Y and cortical astrocytes. MnL4 (10 mM) significantly reduced the
increase in superoxide anion in both cell types, but prevented caspase 3/7 activity only in astrocytes.
MnL4 reduced lipid peroxidation induced by oxaliplatin and normalized the intracellular calcium signal
evoked by ATP and acetylcholine in astrocytes, preincubated with oxaliplatin. MnL4 did not interfere
with the concentration- and time-dependent cytotoxic effects of oxaliplatin on the cancer cell lines HT-
29 and LoVo. In vivo MnL4 reduced the response at mechanical noxious and mechanical and thermal
non-noxious stimuli in oxaliplatin treated animals. Rat rota-rod performances were improved.
Conclusion: Since MnL4 exerts its beneficial effects without interfering with the anticancer activity of
oxaliplatin, it could be proposed as adjuvant to prevent and reduce oxaliplatin induced neuropathy.
& 2016 Elsevier Inc. All rights reserved.1. Introduction
One of the most discomfortable dose-limiting adverse reactions
of effective drugs for the treatment of solid tumors is a neuro-
pathic syndrome accompanied by persistent pain.
The overall incidence of the chemotherapy induced neuropathy
(CIN) is estimated to be approximately 38% in patients treatedopathy; DMEM, Dulbecco’s
BSS, Hanks’ balanced salt
rhodamine 110 bis-(N-CBZ-L-
B, sulforhodamine B; SOD,
c acid reactive substances;
olium bromide; MnL4, 4,10-
acid MnIIwith multiple agents, [1] although this percentage varies de-
pending on chemotherapy regimens, duration of exposure, and
assessment methods [2].
Neuropathic pain in chemotherapy-treated patients often be-
gins simultaneously in the hands and feet and it is the main reason
for dose reduction and discontinuation of life-saving therapy [3].
Studying CIN in animal models in the search of possible ad-
juvant therapies to prevent neuropathy and alleviate pain, we
identified several targets of oxaliplatin toxicity. In a rat model of
oxaliplatin-induced neuropathy, markers of oxidative stress (in-
cluding lipid peroxidation, carbonylated proteins, and DNA oxi-
dation) increased in the systemic circulation, sciatic nerve and
lumbar spinal cord [4]. Oxaliplatin-mediated damage results in
neuronal cell modifications, morphological and molecular altera-
tions in dorsal root ganglia and peripheral nerves [5] and elec-
trophysiological hyperactivity in spinal wide dynamic range
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nervous regions related to pain perception like cortical areas. A
noteworthy involvement of astrocytes has been highlighted and
strongly related to pain hypersensitivity [7].
A role for oxidative stress in the pathobiology of CIN is sup-
ported by multiple in vitro and in vivo studies showing that an-
tioxidants have neuroprotective effects in oxaliplatin toxicity
[4,5,8], suggesting a central involvement of mitochondria in CIN
degenerative alterations. CIN is associated with a significant in-
crease in the incidence of swollen and vacuolated mitochondria in
peripheral nerve axons [9,10]. Oxaliplatin induces significant def-
icits in Complex I-mediated and Complex II-mediated respiration
and significant deficits in ATP production in rat sciatic nerve [11].
Moreover, oxaliplatin promotes apoptosis and a release of cyto-
chrome c from mitochondria to the cytosol in astrocyte cell cul-
tures [12].
The superoxide dismutase enzymes (SOD) can metabolize su-
peroxide ion (O2), reduce O2 toxicity and preserve mi-
tochondrial integrity and functions. Decreased MnSOD activity has
been described in different CIN, depending on SOD nitration linked
to high levels of species with high oxidizing power [13]. Mi-
tochondria are together sources and targets of O2 and other
reactive oxygen species (ROS). Their reduced functionality impairs
cell metabolic and signaling processes, among which is calcium
homeostasis [14]. Calcium dysregulation can induce abnormal
spontaneous discharges in neuronal cells, degeneration of nerve
fibers and central sensitization promoting allodynia and hyper-
algesia [15].
Therefore, we decided to study an efficacious SOD mimetic
compound as a possible adjuvant treatment in CIN. The
polyamine-polycarboxylate-MnII complex 4,10-dimethyl-1,4,7,10
tetraazacyclododecane-1,7-diacetic acid MnII (MnIIMe2DO2A,
herein indicated as MnL4 [16]) is a small, lipophilic molecule,
capable of readily entering into cells and decomposing O2 at
cytoplasmic sites of generation. It contains a Mn(II) ion and this
characteristic determines a potent SOD-mimetic activity able to
reduce ROS toxicity in biological environment. MnL4 shows a high
thermodynamic stability, thus reducing the possibility to release
the metal in biological fluids [16]. MnL4 ameliorates lung in-
flammation, oxidative injury and breathing dysfunction induced
by exposure to the air-borne allergen in sensitized guinea pigs
[17]. The molecule administered both acutely at the dose of
15 mg kg1 or by osmotic pump (15 mg kg1 die for 14 days,
chronic slow release) largely reduces neuropathic and in-
flammatory pain in different models of osteoarthritis and rheu-
matoid arthritis [18]. Moreover, the efficacy of SOD-mimetic
compounds was also described in animal models of inflammatory
and neuropathic pain [19].
According to our previous work [20], the cytotoxicity of ox-
aliplatin can be conveniently studied in isolated neuronal cells
which might generate preliminary data on the effectiveness of
potential adjuvants in CIN treatment and maintenance of ox-
aliplatin anticancer activity. In isolated astrocytes and in the
neuroblastoma cell line SH-SY5Y treated with oxaliplatin, we
studied the effect of MnL4, focalizing our research on direct and
indirect indexes of O2 toxicity, mitochondrial damage and cal-
cium homeostasis, since Ca2þ signaling may be strongly altered by
membrane lipid peroxidation and decrease of mitochondrial en-
ergy production. Moreover, in human colorectal adenocarcinoma
cell lines (HT-29 and LoVo), we analyzed oxaliplatin cytotoxicity in
the absence or presence of MnL4 to evaluate if the antioxidant
treatment can interfere with the antitumor activity of the plati-
num compound. Finally, MnL4 was tested in vivo in a rat model of
CIN.2. Methods
2.1. Animals
For all the experiments described below, male Sprague–Dawley
rats (Harlan, Varese, Italy) weighing approximately 200–250 g at
the beginning of the experimental procedure were used. Animals
were housed in CeSAL (Centro Stabulazione Animali da Labor-
atorio, University of Florence) and used at least one week after
their arrival. Four rats were housed per cage (size 2641 cm2);
animals were fed with standard laboratory diet and tap water ad
libitum, and kept at 2371 °C with a 12 h light/dark cycle, light at
7 a.m. All animal manipulations were carried out according to the
European Community guidelines for animal care (DL 116/92, ap-
plication of the European Communities Council Directive of 24
November 1986 (86/609/EEC). The ethical policy of the University
of Florence complies with the Guide for the Care and Use of La-
boratory Animals of the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996; University of Florence assur-
ance number: A5278-01). Formal approval to conduct the experi-
ments described was obtained from the Italian Ministry of Health
(No. 54/2014-B) and from the Animal Subjects Review Board of the
University of Florence. Experiments involving animals have been
reported according to ARRIVE guidelines [21]. All efforts were
made to minimize animal suffering and to reduce the number of
animals used.
2.2. Materials
All reagents were of the highest chemical purity grade and
were obtained from Sigma-Aldrich (Milano, Italy) unless otherwise
indicated.
The organic ligand 4,10-dimethyl-1,4,7,10-tetra-
azacyclododecane-1,7-diacetic acid (H2L4) was synthesized as
previously reported [16]. This compound was isolated as trihy-
drochloride salt (H2L4 3HCl). Its complex, MnL4, was obtained by
reaction of MnSO4 with H2L4 3HCl (1 : 1 M ratio) in aqueous so-
lution at neutral pH under nitrogen atmosphere; the MnL4 com-
plex was then isolated as a white solid by precipitation with an
ethanol/diethyl ether 2 : 1 mixture, according to a previously de-
scribed procedure [16]. The complex was further purified by re-
crystallization with water/ethanol. The purity of the compound
(495%) was ascertained by elemental analysis [16].
2.3. Cell cultures
Primary cultures of astrocytes were obtained according to the
method described by McCarthy and De Vellis [22]. Briefly, the
cerebral cortex of newborn (P1–P3) Sprague Dawley rats (Harlan,
Italy) was dissociated in Hanks’ balanced salt solution (HBSS)
containing 0.5% trypsin/EDTA and 1% DNAse for 30 min at 37 °C.
The suspension was mechanically homogenized and filtered. Cells
were plated in Dulbecco’s Modified Eagle’s Medium (DMEM) high
glucose with 20% fetal bovine serum (FBS, Gibco, Invitrogen, Italy).
Confluent primary glial cultures were used to isolate astrocytes
removing microglia and oligodendrocytes by shaking. The purity
of astrocyte cultures was determined immunocytochemically by
staining for GFAP (Dako, Denmark). Cells were fixed in 4% paraf-
ormaldehyde, then incubated with the antibody (1:200) and vi-
sualized using Alexafluor conjugated secondary antibody. Nuclei
were stained with 4′,6-diamidino-2-phenylindole dihydrochloride
(DAPI). GFAP-positive cells were 95–98% in astrocyte cultures.
Experiments were performed 21 days after cell isolation. Astro-
cytes were cultured in DMEM high glucose with 10% FBS, 2 mM L-
glutamine, 1% essential aminoacid mix, 100 IU ml1 penicillin and
100 μg ml1 streptomycin in 5% CO2 atmosphere at 37 °C.
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cancer cell lines HT-29 and LoVo were obtained from the American
Type Culture Collection (Rockville, MD). SH-SY5Y were cultured in
DMEM/HAM F12 supplemented with 10% FBS. HT-29 were cul-
tured in DMEM high glucose with 10% FBS, LoVo cells were cul-
tured in Ham’s F12K supplemented with 10% FBS. Media contained
2 mM L-glutamine, 1% essential aminoacid mix, 100 IU ml1 pe-
nicillin and 100 μg ml1 streptomycin. All cell lines were main-
tained under standard culture conditions (37 °C, 5% CO2, 95% air
and 100% relative humidity).
SH-SY5Y, HT-29 and astrocytes were starved in serum-free
DMEM overnight before all treatments. Protein homogenate con-
centrations were measured by bicinchoninic acid assay.
SH-SY5Y were used as such or after treatments to obtain a
neuron-like phenotype according to [23]. The method is ex-
tensively described in Supplementary Methods and Results and
Fig. S1. Briefly, SH-SY5Y cells were treated with retinoic acid 10 mM
for 48, 72, and 120 h in starvation medium. Differentiation was
analyzed by (A) morphological study, evaluating the neurite out-
growth evidenced by the presence of abundant and branched
neuritis; (B) immunocytochemistry for the neuronal marker β-
tubulin III; and (C) western blot to quantify the expression of Stat-
1. The incubation with 10 mM retinoic acid for 72 h was chosen as
optimal condition.
For cell growth inhibition studies two representative human
colon carcinoma cell lines (HT-29 and LoVo) were used.
Cells were incubated with 0.1–100 mM oxaliplatin as indicated
for each protocol type (see below) in the absence or presence of
10 mMMnL4. Time intervals and concentrations used in each set of
experiments were chosen in respect to the method sensibility and
specificity.
2.4. SOD-inhibitable superoxide anion production evaluated by cy-
tochrome c assay
SH-SY5Y (undifferentiated or after neuronal differentiation by in-
cubation with 10 mM retinoic acid for 72 h) or astrocytes were plated
in 6-well plates (5105/well) and grown until confluence. Cells were
then incubated with or without 100 μM oxaliplatin in serum-free
DMEM containing cytochrome c (1 mg/mL) for 4 h at 37 °C, in the
absence or presence of 10 mM MnL4. Non-specific cytochrome c re-
duction (following the reaction Fe3þþO2-Fe2þþO2) was eval-
uated carrying out tests in the presence of bovine SOD (300 mU/mL).
The supernatant of each well was collected, and the optical density
was spectrophotometrically measured at 550 nm. After subtracting
the non-specific absorbance, the SOD-inhibitable O2 amount was
calculated by using an extinction coefficient of 2.1 104 M1 cm1
and expressed as mM/mg protein/4 h (the method is according to
[24]). The 4 h incubation interval was chosen on the basis of pre-
liminary experiments which showed poor reliability for longer cyto-
chrome c exposure to the cellular environment [20].
2.5. Lipid peroxidation (thiobarbituric acid reactive substances,
TBARS)
Astrocytes were plated in cell culture Petri dishes (10 cm dia-
meter, 108/dish) and grown until confluence. Thiobarbituric acid
reactive substances (TBARS) were quantified as an index of lipid
peroxidation after 16 h incubation with 10 mM oxaliplatin in the
absence or presence of 10 mM MnL4 with some minor modifica-
tions [20].
After incubation, cells were scraped and cell suspension un-
derwent a freeze/thaw cycle. The suspension was added to 4 mL
reaction mixture consisting of 36 mM thiobarbituric acid solubi-
lised in 10% CH3COOH, 0.2% SDS, pH was adjusted to 4.0 with
NaOH. The mixture was heated for 60 min at 100 °C and thereaction was stopped by placing the vials in ice bath for 2 h. After
centrifugation (at 1600 g at 4 °C for 10 min) the absorbance of
the supernatant was measured at 532 nm (Perkin-Elmer spectro-
meter) and TBARS were quantified in mmoles/milligram of total
protein using 1,1,3,3-tetramethoxypropane as standard.
2.6. Caspase 3/7 activity
SH-SY5Y cells (undifferentiated or after differentiation in neu-
ron-like phenotype by incubation with 10 mM retinoic acid for
72 h) or astrocytes were plated in 6-well plates (5105/well) and
grown until confluence. Cells were incubated with 100 mM ox-
aliplatin for 4 and 8 h in the absence or presence of 10 mM MnL4.
After treatment, cells were scraped in 100 mL lysis buffer as sup-
plied by the manufacturer. Fifty microliters of the supernatants
was incubated with 25 mM fluorogenic peptide caspases 3 and
7 substrate rhodamine 110 bis-(N-CBZ-L-aspartyl-L-glutamyl-L-va-
lyl-L-aspartic acid amide) (Z-DEVD-R110; Molecular Probes) at
25 °C for 30 min in duplicate. The amount of cleaved substrate in
each sample was measured in a 96-well plate fluorescent spec-
trometer (Perkin-Elmer; excitation at 496 nm and emission at
520 nm).
2.7. Intracellular Ca2þ measurement
Intracellular cytosolic Ca2þ concentration ([Ca2þ]i) was eval-
uated in fura-2 loaded astrocytes. Briefly, l04 cells were plated on
round glass coverslips (25 mm diameter), grown for 2–3 days in
complete medium and then maintained for 16 h in DMEM alone,
DMEMþ10 mM MnL4, DMEMþ10 mM oxaliplatin or
DMEMþ10 mM MnL4þ10 mM oxaliplatin. Cells were loaded with
4 mM fura-2AM (Molecular Probes-Invitrogen Life technologies,
San Giuliano Milanese, Italy) for 45 min at RT and then washed
with HEPES/Tyrode solution of the following composition: (mM):
HEPES 5, D-glucose 10, NaCl 140, KCl 5.4, MgCl2 1.2, and CaCl2 1.8
(pH adjusted to 7.3 with NaOH). Coverslips were mounted in a
perfusion chamber and placed on the stage of an epifluorescence
microscope (TMD Diaphot, Nikon Co, Tokyo, Japan) equipped with
a 75 W Xenon lamp. Fura-2 fluorescence was recorded with an
extended ISIS-M camera (Photonic Science, Roberts Bridge, East
Sussex, UK) and measured by single cell imaging analysis at 35 °C
[25]. Paired experiments were performed for each treatment in at
least 3 different astrocyte preparations. Agonists (i.e. 10 mM ACh or
10 mM ATP) were administrated soon after recording basal fluor-
escence (F) and cytosolic [Ca2þ]i dynamic was evaluated in single
cells as the increase in fluorescence after subtracting the basal
fluorescence (ΔF/F). The area under the curve (AUC) was mea-
sured for 300 s after the administration of the different agonist. A
signal-to-noise ratio of at least 5 arbitrary fluorescence unit (A.U.)
was considered as [Ca2þ]i signal. About 18–20 cells were evaluated
blindly for each experimental protocol.
2.8. Cell viability assay
Cell viability was evaluated by the reduction of 3-(4,5-di-
methylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as an
index of mitochondrial compartment functionality. HT-29 cells
were plated into 96 well cell culture plates, grown until confluence
and treated for 24 and 48 h in control condition or in the presence
of 10 mM MnL4 with different concentrations of oxaliplatin in
DMEM (0–100 mM). After extensive washing, 1 mg/mL MTT was
added into each well and incubated for 2 h at 37 °C. After washing,
the formazan crystals were dissolved in 100 μL dimethyl sulfoxide.
The absorbance was measured at 580 nm. Experiments were
performed in quadruplicate on at least 3 different cell batches.
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The cytotoxic effects of oxaliplatin against HT-29 and LoVo cell
lines, alone or in combination with MnL4 were evaluated ac-
cording to the sulforhodamine B (SRB) assay described by Skekan
et al. [26].
Exponentially growing cells were seeded in 96-well plates in
RPMI 1640 supplemented with 10% FCS at a plating density of
4103 cells/well. After 24 h, the medium was removed and re-
placed with oxaliplatin-containing medium, in the absence or
presence of 10 mM MnL4, for exposure times of 24 h, or 24 h fol-
lowed by regrowth in drug free medium for additional 24 h, or
48 h. After these exposure times, the assay was terminated by the
addition of cold trichloroacetic acid (TCA). Cells were fixed by 10%
TCA and stained by SRB solution at 0.4% (w/v) in 1% acetic acid.
The SRB fixed to the cells was dissolved in 10 mM Tris–HCl and
absorbance was read on an automated plate reader at a wave-
length of 540 nm.
The IC50 drug concentration resulting in a 50% reduction in the
net protein content (as measured by SRB staining) in drug treated
cells as compared to untreated control cells was determined. Each
reported IC50 value represents the mean of three independent
experiments.
2.10. Oxaliplatin-induced neuropathic pain model
Rats were treated with 2.4 mg kg1 oxaliplatin, administered
intraperitoneally (i.p.) for 5 consecutive days every week for three
weeks (15 i.p. injections [27]). Oxaliplatin was dissolved in 5%
glucose solution. Behavioral and biochemical tests were performed
on 21st day. Control animals received an equivalent volume of 5%
glucose i.p. Animal body weight was recorded every 2nd day.
2.11. Drug treatments
MnL4 was given by continuous subcutaneous (s.c.) delivery
using an osmotic minipump (Alzet 2004, Palo Alto, CA, USA) im-
planted by surgical procedure under enflurane anesthesia on the
back and filled to deliver a daily dose of 15 mg kg1 for 21 days
[18].
2.12. Paw pressure test
The nociceptive threshold in the rat was determined with an
analgesimeter (Ugo Basile, Varese, Italy), according to the method
described by Leighton et al. [28]. Briefly, a constantly increasing
pressure was applied to a small area of the dorsal surface of the
paw using a blunt conical probe by a mechanical device. Me-
chanical pressure was increased until vocalization or a withdrawal
reflex occurred while rats were lightly restrained. Vocalization or
withdrawal reflex thresholds were expressed in grams. Rats scor-
ing below 40 g or over 75 g during the test before drug adminis-
tration were rejected (25%). For analgesia measures, mechanical
pressure application was stopped at 120 g. Experiments were
performed blindly.
2.13. Von Frey test
Animals were placed in 20 cm20 cm plexiglas boxes equip-
ped with a metallic meshed floor, 20 cm above the bench. A ha-
bituation of 15 min was allowed before the test. An electronic Von
Frey hair unit (Ugo Basile, Varese, Italy) was used: the withdrawal
threshold was evaluated by applying force ranging from 0 to 50 g
with a 0.2 g accuracy. Punctuate stimulus was delivered to the
mid-plantar area of each anterior paw from below the meshed
floor through a plastic tip and the withdrawal reflex wasautomatically displayed on the screen. Paw sensitivity threshold
was defined as the minimum pressure required to elicit a robust
and immediate withdrawal reflex of the paw. Voluntary move-
ments associated with locomotion were not taken as a withdrawal
response. Stimuli were applied on each anterior paw with an in-
terval of 5 s. The measure was repeated 5 times and the final value
was obtained by averaging the 5 measures [29].
2.14. Cold plate test
Animals were placed on a stainless box (12 cm20 cm
10 cm) with a cold plate as floor. The temperature of the cold plate
was kept constant at 4 °C71 °C by cold circulating water. Pain-
related behaviors (i.e. lifting and licking of the hind paw) were
observed and the time (seconds) of the first sign was recorded. The
cut-off time of the latency of paw lifting or licking was set at 60 s.
2.15. Rota-rod test
Rota-rod apparatus (Ugo Basile, Varese, Italy) consisted of a
base platform and a rotating rod with a diameter of 6 cm and a
non-slippery surface. The rod was placed at a height of 25 cm from
the base. The rod, 36 cm in length, was divided into 4 equal sec-
tions by 5 disks. Thus, up to 4 rats were tested simultaneously on
the apparatus, with a rod-rotating speed of 10 rpm. The integrity
of motor coordination was assessed on the basis of walking time
and the number of falls from the rod for a maximum of 600 s. After
a maximum of 6 falls from the rod, the test was suspended and the
time was recorded.
2.16. Statistic analysis
Results were expressed as means7S.E.M. and the analysis of
variance was performed by one way ANOVA. A Bonferroni’s sig-
nificant difference procedure was used as post-hoc comparison. P
values of less than 0.05 were considered as significant. Data were
analyzed using the “Origins 9.1” software.3. Results
According to our previous results, at least a component of ox-
aliplatin toxicity is dependent on ROS generation; SH-SY5Y line
and freshly isolated astrocytes represent valuable in vitro models
to predict the protective effect of adjuvant molecules on ox-
aliplatin neuropathy [19]. We analyzed several parameters related
to ROS toxicity on these cellular models testing the efficacy of
MnL4.
3.1. SH-SY5Y cells
As already described [19], the incubation with 100 mM ox-
aliplatin for 4 h doubled O2 production in the neuronal cell line
SH-SY5Y (Fig. 1A). MnL4 (10 mM) significantly reduced this in-
crease, without influencing basal release.
At the same concentration, oxaliplatin incubation for 4 and 8 h
significantly increased caspase 3/7 activity (Fig. 1B and C), but the
concurrent administration of 10 mM MnL4 was ineffective, in-
dicating that in this neuroblastoma cell line the apoptotic process
induced by oxaliplatin could be independent to ROS production.
The same experiments were also performed on SH-SY5Y after
differentiation in a more mature neuron-like phenotype by re-
tinoic acid treatment (10 mM for 72 h). O2 concentrations were
similar to that obtained in the undifferentiated cells (both for basal
and stimulated conditions; data not shown). The incubation with
oxaliplatin for 4 h did not modify the activity of caspase 3/7,
Fig. 1. Effect of 10 mM MnL4 on SOD-inhibitable O2 concentration (A) and cas-
pase 3/7 activity at 4 (B) and 8 h (C) in SH-SY5Y. Panel A: SH-SY5Y cells were ex-
posed to 100 μM of oxaliplatin for 4 h in the absence or presence of 10 mM MnL4.
O2 concentration was evaluated by cytochrome c assay. The non-specific absor-
bance was measured for each sample in the presence of SOD (300 mU/mL) and
subtracted to the total value. Each value represents the mean7S.E.M. of 4 experi-
ments. Panels B and C: Caspase 3/7 activity in SH-SY5Y. Cells were incubated with
oxaliplatin (100 μM) in the absence or presence of 10 mM MnL4 for 4 (B) or 8 h (C).
Caspase 3/7 activity was measured using the fluorescent substrate Z-DEVD-R110.
Values are expressed as percent of control caspase 3/7 activity arbitrarily set as
100%. Each value represents the 7S.E.M. of 3 experiments. *Po0.01 versus control.
Segments on the top of bars indicate the significance versus basal values.
Fig. 2. Effect of 10 mM MnL4 on SOD-inhibitable O2 concentrations (A) and
caspase 3/7 activity at 4 (B) and 8 h (C) in astrocytes. Panel A: astrocytes were
exposed to 100 μM of oxaliplatin for 4 h in the absence or presence of 10 mMMnL4.
O2 concentration was evaluated by cytochrome c assay. The non-specific absor-
bance was measured for each sample in the presence of SOD (300 mU/mL) and
subtracted to the total value. Each value represents the mean7S.E.M. of 4 experi-
ments. Panels B and C: Caspase 3/7 activity in astrocytes. Cells were incubated with
oxaliplatin (100 μM) in the absence or presence of 10 mM MnL4 for 4 (B) or 8 h (C).
Caspase 3/7 activity was measured using the fluorescent substrate Z-DEVD-R110.
Values are expressed as percent of control caspase 3/7 activity arbitrarily set as
100%. Each value represents the 7S.E.M. of 3 experiments. *Po0.01 versus control.
Segments on the top of bars indicate the significance versus basal values.
Table 1
Effect of MnL4 on astrocytes lipoperoxidation to oxaliplatin.
Thiobarbituric reactive substances (mM/mg total proteins)
Basal value 10 mM Oxaliplatin
Control 15.271.2 41.471.2n
10 mM MnL4 13.172.3 23.673.3n^
Astrocytes were exposed to 10 μM oxaliplatin for 16 h in the absence or presence of
MnL4. TBARS (tiobarbituric acid reactive substances) assay was used to evaluate
lipid peroxidation. Calibration curves were performed with malonyl aldehyde
(MDA). Values are expressed as the mean7S.E.M. of 5 experiments. *Po0.01
versus their respective control and P^o0.01 versus oxaliplatin alone treatment.
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(694776% in comparison to the basal value 10072.3%). MnL4 did
not reduce caspase 3/7 activation (638741%).
3.2. Astrocytes
Since astrocytes participate to the neuropathy induced by the
chemotherapic agent [7], the effect of MnL4 was evaluated on
these glial cells. Astrocytes production of O2 was increased
more than 6 times by 100 mM oxaliplatin (4 h). MnL4 strongly
reduced this production, while the basal release was only mar-
ginally decreased (Fig. 2A).
At the same concentration, oxaliplatin significantly increased
caspase 3/7 activity at 4 and 8 h (Fig. 2B and C); the con-
temporaneous administration of 10 mM MnL4 significantly de-
creased caspase 3/7 activity, suggesting that in these non-neo-
plastic cells the apoptotic process could be dependent on ROS
production.
MnL4 reduced lipid peroxidation induced by 10 mM oxaliplatin
incubation for 16 h. Indeed, oxaliplatin increased lipid peroxida-
tion more than twice (Table 1) in the controls, while in the pre-
sence of 10 mM MnL4, the increase was strongly reduced (Table 1).
Then, we measured the kinetics of [Ca2þ]i increase elicited byATP and ACh in control and oxaliplatin preincubated astrocytes. As
shown, 10 mM ATP induced a sustained, oscillatory calcium in-
crease in astrocytes (Fig. 3). The preincubation with 10 mM ox-
aliplatin for 16 h amplified the effect of ATP. In cells preincubated
with oxaliplatin, the AUC was increased by 60% (Fig. 3, inset). The
preincubation with 10 mMMnL4 (16 h) did not modify ATP calcium
kinetic in control condition (Fig. 3, inset), but restored ATP signal
in cells pretreated with oxaliplatin (contemporaneous preincuba-
tion with oxaliplatin and MnL4). Similarly, the calcium transient
Fig. 3. Effect of ATP on intracellular cytosolic calcium concentration on astrocytes.
Typical time-courses of [Ca2þ]i recorded in control, 10 mM oxaliplatin (16 h pre-
treatment) and 10 mM MnL4þ10 mM oxaliplatin are shown. ATP (10 mM) was ad-
ministered at time 0 and maintained throughout the experimental time. For sim-
plicity, the [Ca2þ]i dynamic obtained in cells preincubated with 10 mM MnL4 alone
is omitted. Abscissa: time (s), Ordinate: fluorescence intensity reported as ΔF/F.
Inset shows the AUC (area under the curve, arbitrary units) calculated in the in-
terval 0–300 s. ***Po0.001 versus all other groups.
Fig. 5. Effect of 10 mM MnL4 on oxaliplatin toxicity in HT-29. Cell viability. Viability
of HT-29 cells was quantified by MTT assay after incubation with oxaliplatin (0–
100 μM) for 24 (A) or 48 h (B). Absorbance was measured at 550 nm and values
were expressed in percentage of control (0 μM oxaliplatin) as mean7S.E.M. of
6 experiments. *Po0.05 versus the respective oxaliplatin alone concentration.
MnL4 (10 mM) alone did not influence cell viability.
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tion with 10 mM oxaliplatin (Fig. 4) and MnL4 restored ACh signal
as evaluated by the AUC (Fig. 4, inset).
3.3. HT-29 cell line
Aimed to evaluate a possible interaction between the anti-
oxidant treatment and the therapeutic property of oxaliplatin, we
evaluated oxaliplatin-induced cytotoxicity in the presence of MnL4
in a human colon cancer cell line HT-29 sensitive to this drug.
Fig. 5 shows the concentration-dependent oxaliplatin (0.1–
100 mM) lethal effect after 24 (Fig. 5A) or 48 h (Fig. 5B) incubation
in the absence and presence of 10 mMMnL4. MnL4 (10 mM) did not
significantly modify oxaliplatin cytotoxicity after 24 h but sig-
nificantly increased it after 48 h.Fig. 4. Effect of acetylcholine (ACh) on intracellular cytosolic calcium concentration
on astrocytes. Typical time-courses of [Ca2þ]i recorded in control, 10 mM oxaliplatin
(16 h pre-treatment) and 10 mM MnL4þ10 mM oxaliplatin are shown. ACh (10 mM )
was administered at time 0 and maintained throughout the experimental time. For
simplicity, the [Ca2þ]i dynamic obtained in cells preincubated with 10 mM MnL4
alone is omitted. Abscissa: time (s), Ordinate: fluorescence intensity reported as ΔF/
F. Inset shows the AUC (area under the curve, arbitrary units) calculated in the
interval 0–300 s. **Po0.01 versus all other groups.Antiproliferative effects of oxaliplatin alone or in combination
with 10 mM of MnL4 on HT29 cells were also measured after 24 h
(followed by regrowth in drug free medium for 24 h) and 48 h
with SRB assay.
The resulting concentration–response curves are shown in
Fig. 6A. As well as in the MTT assay, no significant differences in
the cytotoxic effects of oxaliplatin when combined with MnL4
were observed.
3.4. LoVo cell line
The cytotoxic effects of oxaliplatin alone or in combination with
MnL4 10 μM were also evaluated in LoVo cells (human colon
cancer cell line intrinsically resistant to oxaliplatin) with SRB assay
(Fig. 6B).
Similarly as observed for the cell line HT-29 any change in the
cytotoxic effects of oxaliplatin when combined with MnL4 was
observed.
3.5. Oxaliplatin-induced neuropathic pain model
As already described, 5 days/week for 3 weeks of oxaliplatin
administration (i.p., 2.4 mg kg1 daily) induced a progressive
neuropathy characterized by mechanical hypersensitivity and re-
duced pain threshold to non-noxious stimuli [5]. After 3 weeks,
the weight tolerated on the posterior paw decreased by about 50%
in oxaliplatin-treated animals (mechanical hypersensitivity to a
noxious stimulus, Fig. 7A). As measured with the electronic Von
Frey apparatus, control withdrawal threshold to the mechanical
non-noxious stimulus was decreased in oxaliplatin treated animals
by 30% (Fig. 7B). The threshold decrease of a non-painful thermal
stimulus was measured by the licking latency on cold plate. Re-
sults showed that oxaliplatin treatment decreased licking latency
by 60% (Fig. 7C). The administration of MnL4 by slow, continuous
delivery with osmotic pump (15 mg kg1 daily) in oxaliplatin
treated animals improved neuropathic symptoms as compared to
oxaliplatin alone (Fig. 7A–C). Moreover, the walking time and the
number of falls on a rotating rod (Rota-rod test) were impaired as
a consequence of CIN. Indeed, oxaliplatin-treated rats balanced on
the rotating rod less than 1/3rd (Fig. 8A) and failed down 9 times
more frequently than control rats (Fig. 8B). MnL4 ameliorated
Fig. 6. Effect of 10 mMMnL4 on oxaliplatin toxicity in HT-29 and LoVo. Cell growth inhibition. The antiproliferative activity of oxaliplatin, alone or in combination with 10 mM
MnL4, was evaluated in HT29 (A) and LoVo (B) human colorectal carcinoma cell lines. The results (evaluated according to the sulforhodamine B assay) after exposure times of
24 h, or 24 h followed by regrowth in drug free medium for additional 24 h, or 48 h are shown. Absorbance was measured at 540 nm and values were expressed in
percentage of control (0 μM oxaliplatin) as mean7S.E.M. of 3 experiments. Each reported IC50 value represents the mean of three independent experiments.
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and B) as a consequence of the reduced pain even if it did not
recover the highly significant negative effect in body growth in-
duced by oxaliplatin treatment (Fig. 8C). These results suggested
that MnL4 reduced neuropathy, although it did not modify the
systemic toxicity of oxaliplatin.4. Discussion
Platinum anticancer drugs are effective treatments for several
malignancies [30–32]. Oxaliplatin possesses a relative low hema-
tological and gastrointestinal toxicity, but CIN can limit its clinical
use [33,34]. Therefore, many efforts have been addressed to find
adjuvant strategies to reduce CIN.
In our research, we have already characterized ROS as central
players of oxaliplatin CIN using in vitro and in vivo models
[4,20,35]. The results herein presented show that the SOD mimetic
poliaminopolicarboxylic compound MnL4 prevents cellular da-
mage induced by oxaliplatin in vitro, reducing oxidative stress and
normalizing calcium dynamic in isolated astrocytes pre-treated
with the anticancer drug. Moreover, it reduces CIN in rats when
continuously administered by osmotic pump in the course of ox-
aliplatin treatment. MnL4 has been already characterized as a
membrane permeable, high effective O2 scavenger compound
[16], possessing anti-inflammatory properties in allergic asthma
[17] and behaving as a potent pain reliever in acute and chronic
articular pathologies [18].
In vitro, MnL4 prevents the increase in O2 induced by ox-
aliplatin incubation without significantly influencing the basal
release in the neuroblastoma cell line SH-SY5Y and astrocyteprimary cultures. Oxaliplatin induces a six-fold increased O2
production in primary astrocytes, whereas in SH-SY5Y O2 is
increased two-fold; to note, the basal control level of O2 pro-
duction in the neuroblastoma cell line is more than twenty-fold
higher than in astrocytes. This different production of O2 in
basal control conditions suggests that SH-SY5Y cells are adapted to
survive in a ROS rich environment and can be less sensible to the
oxidative toxicity. By measuring caspase 3/7 activity a different
behavior is observed in astrocytes and SH-SY5Y. In both cell types,
caspase 3/7 activity is increased by oxaliplatin incubation in a
time-dependent mode. In astrocytes, the concomitant incubation
with MnL4 reduces it, whereas in SH-SY5Y, MnL4 is ineffective. An
anti-apoptotic effect of antioxidants has been described in SH-
SY5Y treated with noxious stimuli like MPPþ [36], 1,2-diace-
tylbenzene [37] or hydrogen peroxide [38]. In those reports, an
exogenous oxidant stimulus has been employed; on the contrary,
as already described [20], oxaliplatin is not a direct oxidant mo-
lecule. Its oxidative power is elicited only in whole cells, sug-
gesting the need of a cellular environment to evoke O2
overproduction.
We have already described that oxaliplatin might regulate two
distinct pathways (mitochondrial-dependent or not) converging to
the activation of the final apoptotic marker caspase 3 in the pri-
mary, non-neoplastic astrocyte culture and in cancer cell lines [12].
This dissimilar behavior of MnL4 in neuroblastoma cells and as-
trocytes might reside in a specific tolerance of SH-SY5Y to a high
oxidative environment (due to the elevated O2 production in
control condition) or to the comparative reduced importance of
mitochondrial ATP level in cancer cells as originally suggested by
Warburg [39]. Mutations in oncogenes and tumor suppressor
genes cause alterations to multiple intracellular signaling
Fig. 7. Effect of MnL4 (15 mg kg1 daily) on mechanical hypersensitivity to a
noxious stimulus (Paw-pressure test, A) and reduced pain threshold to non-noxious
mechanical (Von Frey test, B) and thermal (Cold plate test, C) stimuli induced by
oxaliplatin. Rats were daily intraperitoneally treated with 2.4 mg kg1 oxaliplatin
(dissolved in 5% glucose), five days/week. Tests were performed at day 21. MnL4 (15
mg kg1 daily, dissolved in saline) was administered by slow, continuous infusion
with minipumps (Alzets 2004) for 21 days starting from the first day of oxaliplatin
administration. Control animals were treated with vehicles. Each value represents
the mean of 6 rats per group. nnPo0.01 versus controls. P^o0.05 and P^o0.01
versus oxaliplatin.
Fig. 8. Effect of MnL4 (15 mg kg1 daily) on motor coordination and weight
growth in oxaliplatin-treated rats. The integrity of the animals’ motor coordination
was assessed using a rota-rod apparatus. Rats were placed on a rotating rod
(10 rpm) for a maximum of 600 s. The time spent in the balance (A) and the
number of falls from the rod (B) were recorded. Panel C shows the effect of the
treatments on weight growth as an index of systemic toxicity of oxaliplatin. Rats
were daily intraperitoneally treated with 2.4 mg kg1 oxaliplatin (dissolved in 5%
glucose), five days/week. Tests were performed at day 21. MnL4 (15 mg kg1 daily,
dissolved in saline) was administered by slow, continuous infusion with mini-
pumps (Alzets 2004) for 21 days starting from the first day of oxaliplatin admin-
istration. Control animals were treated with vehicles. Each value represents the
mean7S.E.M. of 6 rats per group. **Po0.01 versus controls. P^o0.01 versus
oxaliplatin.
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oxidized redox environment and enhanced resistance to the mi-
tochondrial pathway to apoptosis [41]. Nevertheless, MnL4 did not
prevent oxaliplatin-induced apoptosis either in SH-SY5Y differ-
entiated to a more mature neuron-like phenotype (by retinoic
acid). On the other hand, despite several morphological and mo-
lecular neuronal features of the differentiated cells, the persistence
of cancer characteristics cannot be excluded. Among others, a high
basal oxidative environment (O2 concentration) is shown in SH-
SY5Y before and after differentiation.To reinforce this indication, we performed experiments on HT-
29 and LoVo colon adenocarcinoma cancer cell lines, testing via-
bility of these cells incubated for 24 h (followed by regrowth in
drug free medium for 24 h) and 48 h with increasing concentra-
tions of oxaliplatin. The concentration-dependent lethal effect of
oxaliplatin is not reduced by the simultaneous co-incubation with
10 mM MnL4, suggesting that in these cancer cell lines the cyto-
toxic mechanism is independent to ROS. This diversity could be
important if MnL4 were to be used as adjuvant therapy during
treatments with platinum anti-neoplastic drugs: MnL4 does not
L. Di Cesare Mannelli et al. / Free Radical Biology and Medicine 93 (2016) 67–76 75interfere with oxaliplatin-induced caspase 3/7 activation in cancer
cells and it could preserve the anticancer effect of oxaliplatin.
Astrocytes express many neurotransmitter receptors coupled to
intracellular Ca2þ mobilization [42,43] and modulated in-
dependent of neuronal signaling [44,45]. This calcium signal
contributes to nociceptive signaling in chronic pain [46–49] and to
the spread of central sensitization [50,51].
ATP and ACh are potent agonists for calcium increase in cortical
astrocytes [52–54] and strongly involved in nociception [55,56] as
well as in oxaliplatin-induced neuropathic pain [57,58]. In our
research, astrocytes pretreated with oxaliplatin are significantly
more reactive to ATP and ACh than control cells when intracellular
calcium is monitored and this hyper-activation is prevented by the
concurrent incubation with MnL4. This protective effect is ob-
served when cells are stimulated with either ATP or ACh, therefore
it seems likely that common mechanisms could be implicated. A
gradient higher than 10 times is present between resting cytosolic
calcium and the extracellular compartment and a similar gradient
exists between cytosol, internal organelles and sarco-endoplasmic
reticulum [46,59]. The maintenance of this physiological cellular
calcium gradient and compartmentalization is strictly dependent
on the energetic status of the cell and the selective plasmalemma
ion permeability: it is of primary importance in intracellular Ca2þ
signaling. Oxidative stress as well as many other pathological
conditions may alter mitochondria, reducing their capability to
produce energy and altering the fine intracellular calcium reg-
ulation. The plasmalemma and other intracellular membranes (i.e.
sarco-endoplasmic reticulum, other organelles, including mi-
tochondria) are compromised by ROS attack and lipid peroxidation
[60].
The increase in caspase 3/7 activity and TBARS in astrocytes
incubated with oxaliplatin strongly suggests that mitochondria are
damaged and the integrity of cell membranes is compromised,
bringing about an altered pathophysiological calcium regulation.
MnL4 restores calcium regulation as a consequence of its scaven-
ging property which prevents caspase 3/7 activation and lipid
peroxidation induced by oxaliplatin. This mechanism may reduce
astrocyte activation and ameliorate CIN.
In vivo, in oxaliplatin-treated rats MnL4 increases pain
threshold, reduces hypersensitivity and improves equilibrium on
rota-rod test. Since the physiological body growth is still ham-
pered in oxaliplatin/MnL4 treated rats as in oxaliplatin alone, it
seems that the reduction of CIN symptoms elicited by MnL4 is
based on a specific antineuropathic mechanism on nervous cells.
According to the results obtained on cells, the anti-neuropathic
effect of MnL4 could be dependent on the scavenging property of
the SOD-mimetic which can preserve astrocyte functionality,
without interfering with the toxic, therapeutic effect of the plati-
num drug on neoplastic cells as demonstrated in HT-29 and LoVo
cells.
In conclusion, according to data presented herein, MnL4 pos-
sesses a pharmacological profile conferring good characteristics
for using this molecule as adjuvant therapy in the treatment of
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